Anti-Cancer Medicines Availability Study
Study objectives: to provide health authorities with data on the availability of licensed anti-neoplastic medicines in Europe and worldwide
Cancer patients are ending up in debt because they have to cover the costs of treatment as well as other care related expenses. The accompanying ESMO Asia 2016 press release can be viewed here.
- to provide health authorities with data on the availability of licensed anti-neoplastic medicines
- to report on the actual availability of anti-neoplastic medicines to patients when they are prescribed and when patients can afford them
- to provide data so that policy makers can decide how to best address and resolve the challenges identified